RU2018136760A - НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ - Google Patents
НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ Download PDFInfo
- Publication number
- RU2018136760A RU2018136760A RU2018136760A RU2018136760A RU2018136760A RU 2018136760 A RU2018136760 A RU 2018136760A RU 2018136760 A RU2018136760 A RU 2018136760A RU 2018136760 A RU2018136760 A RU 2018136760A RU 2018136760 A RU2018136760 A RU 2018136760A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- sequence
- peptide
- cst
- motif
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 28
- 230000002163 immunogen Effects 0.000 title claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102000043131 MHC class II family Human genes 0.000 claims 3
- 108091054438 MHC class II family Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diabetes (AREA)
Claims (22)
1. Выделенный иммуногенный пептид длиной от 12 до 100 аминокислот, содержащий CD1d-связывающий пептидный эпитоп антигена с мотивом последовательности [FWYHT]-X(2)-[VILM]-X(2)-[FWYHT] [SEQ ID NO: 60], и непосредственно прилегающий к указанному эпитопу или отделенный не более чем 7 аминокислотами от указанного эпитопа редокс-мотив последовательности [HW]-X(0,2)-C-X(2)-[CST] ([SEQ ID NO: 1], [SEQ ID NO: 2], [SEQ ID NO: 3]) или [CST]-X(2)-C-X(0,2)-[HW] ([SEQ ID NO: 4], [SEQ ID NO: 5], [SEQ ID NO: 6]), для применения в качестве лекарственного средства, при условии, что указанный пептид не содержит в своей последовательности Т-клеточный эпитоп МНС класса II.
2. Пептид по п. 1 для применения по п. 1 при условии, что указанный антиген не содержит в своей последовательности указанный CD1d-связывающий пептидный мотив на расстоянии в пределах 10 аминокислот от указанного эпитопа.
3. Пептид по п. 1 или 2 для применения по п. 1, в котором CD1d-связывающий мотив пептидной последовательности представляет собой [FWY]-X(2)-[VILM]-X(2)-[FWY] [SEQ ID NO: 63].
4. Пептид по любому из пп. 1-3 для применения по п. 1, в котором редокс-мотив представляет собой [HW]-C-X(2)-[CST] [SEQ ID NO: 1] или [CST]-X(2)-C-[HW] [SEQ ID NO: 4].
5. Пептид по любому из пп. 1-4 для применения по п. 1, в котором редокс-мотив представляет собой [HW]-C-X(2)-C [SEQ ID NO: 7] или C-X(2)-C-[HW] [SEQ ID NO: 10].
6. Пептид по любому из пп. 1-5 для применения по п. 1, в котором редокс-мотив представляет собой Н-С-Х(2)-С [SEQ ID NO: 48] или С-Х(2)-С-Н [SEQ ID NO: 42].
7. Пептид по любому из пп. 1-6 для применения по п. 1, длина которого составляет от 12 до 50 аминокислот.
8. Выделенный иммуногенный пептид длиной от 12 до 100 аминокислот, содержащий CD1d-связывающий пептид антигена с мотивом последовательности [FWYHT]-X(2)-[VILM]-X(2)-[FWYHT] [SEQ ID NO: 60], и непосредственно прилегающий к указанному эпитопу или отделенный не более чем 7 аминокислотами от указанного эпитопа редокс-мотив последовательности [HW]-X(0,2)-C-X(2)-[CST] ([SEQ ID NO: 1], [SEQ ID NO: 2], [SEQ ID NO: 3]) или [CST]-X(2)-C-X(0,2)-[HW] ([SEQ ID NO: 4], [SEQ ID NO: 5], [SEQ ID NO: 6]),
при условии, что указанный пептид не содержит в своей последовательности Т-клеточный эпитоп МНС класса II.
9. Пептид по п. 8, при условии, что указанный антиген не содержит в своей последовательности указанного CD1d-связывающего пептидного мотива на расстоянии в пределах 10 аминокислот от указанной последовательности редокс-мотива.
10. Пептид по п. 8 или 9, который имеет длину от 12 до 50 аминокислот.
11. Пептид по любому из пп. 8-10, в котором последовательность редокс-мотива представляет собой [HW]-C-X(2)-[CST] [SEQ ID NO: 1] или [CST]-X(2)-C-[HW] [SEQ ID NO: 4].
12. Пептид по любому из пп. 8-11, в котором последовательность редокс-мотива представляет собой H-C-X(2)-[CST] [SEQ ID NO: 101] или [CST]-X(2)-C-H [SEQ ID NO: 102].
13. Пептид по любому из пп. 8-12, в котором последовательность редокс-мотива представляет собой Н-С-Х(2)-С [SEQ ID NO: 48] или С-Х(2)-С-Н [SEQ ID NO: 42].
14. Способ получения популяции NKT клеток, которые являются цитолитическими по отношению к клеткам, презентирующим антиген с CD1d-связывающим пептидным эпитопом, включающий стадии:
- предоставления клеток периферической крови;
- контактирования указанных клеток in vitro с иммуногенным пептидом длиной от 12 до 100 аминокислот, содержащим CD1d-связывающий пептидный эпитоп антигена с мотивом последовательности [FWYHT]-X(2)-[VILM]-X(2)-[FWYHT] [SEQ ID NO: 60] и непосредственно прилегающий к указанному эпитопу или отделенный не более чем 7 аминокислотами от указанного эпитопа редокс-мотив последовательности [HW]-X(0,2)-C-X(2)-[CST] ([SEQ ID NO: 1], [SEQ ID NO: 2], [SEQ ID NO: 3]) или [CST]-X(2)-C-X(0,2)-[HW] ([SEQ ID NO: 4], [SEQ ID NO: 5], [SEQ ID NO: 6]), где указанный пептид не содержит в своей последовательности Т-клеточного эпитопа молекулы МНС класса II; и
- экспансии указанных клеток в присутствии IL-2.
15. Способ получения пептида, содержащий стадию:
- идентификации в пределах антигена последовательности с [FWYHT]-X(2)-[VILM]-X(2)-[FWYHT] [SEQ ID NO: 60] мотивом последовательности;
- получения пептида длиной от 12 до 100 аминокислот, содержащего вышеуказанную идентифицированную последовательность и непосредственно прилегающий к указанной последовательности или отделенный не более чем 7 аминокислотами от указанной последовательности редокс-мотив последовательности [HW]-X(0,2)-C-X(2)-[CST] ([SEQ ID NO: 1], [SEQ ID NO: 2], [SEQ ID NO: 3]) или [CST]-X(2)-C-X(0,2)-[HW] ([SEQ ID NO: 4], [SEQ ID NO: 5], [SEQ ID NO: 6]),
при условии, что указанный пептид не содержит в своей последовательности Т-клеточный эпитоп МНС класса II.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16166054.3 | 2016-04-19 | ||
| EP16166054 | 2016-04-19 | ||
| PCT/EP2017/059302 WO2017182528A1 (en) | 2016-04-19 | 2017-04-19 | Novel immunogenic cd1d binding peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018136760A true RU2018136760A (ru) | 2020-05-19 |
| RU2018136760A3 RU2018136760A3 (ru) | 2020-05-27 |
Family
ID=56024090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018136760A RU2018136760A (ru) | 2016-04-19 | 2017-04-19 | НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11485768B2 (ru) |
| EP (1) | EP3445390A1 (ru) |
| JP (2) | JP7320947B2 (ru) |
| KR (3) | KR20180134935A (ru) |
| CN (1) | CN109069605B (ru) |
| AU (2) | AU2017252192C1 (ru) |
| BR (1) | BR112018071466A2 (ru) |
| CA (1) | CA3019266A1 (ru) |
| IL (1) | IL262286B2 (ru) |
| RU (1) | RU2018136760A (ru) |
| SG (1) | SG11201808710UA (ru) |
| WO (1) | WO2017182528A1 (ru) |
| ZA (1) | ZA201806860B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2476435B1 (en) | 2006-08-11 | 2017-12-20 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in immune disorders |
| ES2545886T3 (es) | 2008-02-14 | 2015-09-16 | Life Sciences Research Partners Vzw | Inmunoterapia dirigida a patógenos intracelulares |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| AU2016328582B2 (en) | 2015-09-25 | 2022-11-24 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| US20210401976A1 (en) * | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
| AU2020273597A1 (en) | 2019-05-16 | 2021-11-18 | Imcyse Sa | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
| TW202208413A (zh) | 2020-05-06 | 2022-03-01 | 比利時商伊賽斯公司 | 用於治療多發性硬化症之肽及方法 |
| JP2023525276A (ja) * | 2020-05-06 | 2023-06-15 | アンシス・エスア | 延長された酸化還元酵素モチーフを有する免疫原性ペプチド |
| CA3182369A1 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
| EP4430067A2 (en) * | 2021-11-10 | 2024-09-18 | Tscan Therapeutics, Inc. | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof |
| CN114196629B (zh) * | 2021-12-23 | 2024-02-27 | 珠海贝索细胞科学技术有限公司 | 一种高效培养nkt细胞的试剂及其应用和nkt细胞的培养方法 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985004103A1 (en) | 1984-03-09 | 1985-09-26 | Scripps Clinic And Research Foundation | Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4886782A (en) | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
| US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| HU9300877D0 (en) | 1990-09-27 | 1993-06-28 | Syntello Vaccine Dev Kb | Method for producing proteines applicables by injection and inducing anti-bodies having neutralizing effect against virus of human immun insufficiency |
| WO1993008279A1 (en) | 1991-10-16 | 1993-04-29 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US5824315A (en) | 1993-10-25 | 1998-10-20 | Anergen, Inc. | Binding affinity of antigenic peptides for MHC molecules |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
| US6399383B1 (en) | 1997-10-28 | 2002-06-04 | Maxygen, Inc. | Human papilloma virus vectors |
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
| US20030152581A1 (en) | 1998-07-30 | 2003-08-14 | Jean-Marie Saint-Remy | Compound and method for the prevention and/or the treatment of allergy |
| JP2002529112A (ja) | 1998-11-17 | 2002-09-10 | ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム | Ｈｉｖ特異的ｔ細胞誘導 |
| GB0006437D0 (en) | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
| EP2236611A1 (en) | 2000-04-28 | 2010-10-06 | Novozymes A/S | Lipolytic enzyme variant |
| WO2002000892A1 (en) | 2000-06-26 | 2002-01-03 | Glaxosmithkline Biologicals S.A. | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| EP1409650B1 (en) | 2001-05-30 | 2006-04-12 | Fondazione Telethon | Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof |
| US20050107256A1 (en) | 2001-10-03 | 2005-05-19 | Barnwell Stephen G. | Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| WO2003072731A2 (en) | 2002-02-21 | 2003-09-04 | Apovia, Inc. | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
| US20100183652A1 (en) | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
| JP4406607B2 (ja) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
| ATE432291T1 (de) | 2002-09-12 | 2009-06-15 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
| EP1556072B1 (en) * | 2002-09-17 | 2010-05-19 | Antigen Express, Inc. | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES |
| JP2004147649A (ja) | 2002-10-11 | 2004-05-27 | Kumamoto Technology & Industry Foundation | 頭頚部癌の抗原 |
| WO2005012502A2 (en) | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| US7651855B2 (en) | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| GB0324265D0 (en) | 2003-10-16 | 2003-11-19 | Medical Res Council | Peptide |
| US20070184023A1 (en) | 2003-10-30 | 2007-08-09 | Pharmexa A/S | Method for down-regulation of vegf |
| JP2008044848A (ja) | 2004-11-30 | 2008-02-28 | Univ Kurume | Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| FR2898275B1 (fr) | 2006-03-10 | 2012-12-14 | Genethon | Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire |
| WO2007135684A2 (en) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
| EP2476435B1 (en) | 2006-08-11 | 2017-12-20 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in immune disorders |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| CA2700618A1 (en) | 2007-09-27 | 2009-04-02 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
| EP2249864B1 (en) | 2008-02-14 | 2016-05-04 | Life Sciences Research Partners VZW | Strategies to prevent and/or treat immune responses to soluble allofactors |
| ES2545886T3 (es) | 2008-02-14 | 2015-09-16 | Life Sciences Research Partners Vzw | Inmunoterapia dirigida a patógenos intracelulares |
| EP2245059B1 (en) | 2008-02-14 | 2017-09-20 | Life Sciences Research Partners VZW | Cd4+ t-cells with cytolytic properties |
| EP2252329B1 (en) | 2008-02-14 | 2015-06-17 | Life Sciences Research Partners VZW | Elimination of immune responses to viral vectors |
| CA2715488C (en) | 2008-02-14 | 2019-09-24 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
| WO2009100505A1 (en) | 2008-02-14 | 2009-08-20 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in transplantati |
| WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| KR101022649B1 (ko) | 2008-08-07 | 2011-03-22 | 삼성모바일디스플레이주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치 |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US8647879B2 (en) * | 2009-08-14 | 2014-02-11 | Polytechnic Institute Of Nyu | Peptide probe for rapid and specific detection of β-amyloid aggregation |
| EP3156068B1 (en) | 2010-03-29 | 2021-11-03 | CNRS (Centre National de la Recherche Scientifique) | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof |
| CA2818536C (en) * | 2010-11-25 | 2020-04-28 | Imnate Sarl | Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells |
| PL2643345T3 (pl) | 2010-11-25 | 2021-08-16 | Imnate Sarl | Immunogenne peptydy do zastosowania w zapobieganiu i/lub leczeniu chorób zakaźnych, chorób autoimmunologicznych, odpowiedzi immunologicznych na czynniki allogeniczne, chorób alergicznych, nowotworów, odrzuceniu przeszczepów oraz odpowiedzi immunologicznych skierowanych przeciwko wektorom wirusowym stosowanym w terapii genowej lub szczepieniu genowym |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| KR20150010699A (ko) | 2012-02-15 | 2015-01-28 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 적혈구 결합요법 |
| AU2013255888A1 (en) * | 2012-04-30 | 2014-10-23 | Imcyse Sa | Methods for induction of antigen-specific regulatory T cells |
| US9603948B2 (en) * | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201319160D0 (en) | 2013-10-30 | 2013-12-11 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
| GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| AU2016328582B2 (en) | 2015-09-25 | 2022-11-24 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
-
2017
- 2017-04-19 JP JP2018555682A patent/JP7320947B2/ja active Active
- 2017-04-19 KR KR1020187031509A patent/KR20180134935A/ko not_active Ceased
- 2017-04-19 SG SG11201808710UA patent/SG11201808710UA/en unknown
- 2017-04-19 CA CA3019266A patent/CA3019266A1/en active Pending
- 2017-04-19 WO PCT/EP2017/059302 patent/WO2017182528A1/en active Application Filing
- 2017-04-19 IL IL262286A patent/IL262286B2/en unknown
- 2017-04-19 KR KR1020227031956A patent/KR20220132023A/ko not_active Ceased
- 2017-04-19 BR BR112018071466-6A patent/BR112018071466A2/pt unknown
- 2017-04-19 RU RU2018136760A patent/RU2018136760A/ru not_active Application Discontinuation
- 2017-04-19 KR KR1020247002453A patent/KR20240015731A/ko not_active Withdrawn
- 2017-04-19 US US16/091,549 patent/US11485768B2/en active Active
- 2017-04-19 CN CN201780024518.0A patent/CN109069605B/zh active Active
- 2017-04-19 AU AU2017252192A patent/AU2017252192C1/en active Active
- 2017-04-19 EP EP17721070.5A patent/EP3445390A1/en active Pending
-
2018
- 2018-10-15 ZA ZA2018/06860A patent/ZA201806860B/en unknown
-
2021
- 2021-12-10 JP JP2021200876A patent/JP2022022423A/ja active Pending
-
2022
- 2022-05-27 AU AU2022203627A patent/AU2022203627A1/en not_active Abandoned
- 2022-09-23 US US17/934,607 patent/US20230265156A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL262286B2 (en) | 2023-12-01 |
| AU2017252192B2 (en) | 2022-03-03 |
| EP3445390A1 (en) | 2019-02-27 |
| ZA201806860B (en) | 2021-05-26 |
| SG11201808710UA (en) | 2018-11-29 |
| BR112018071466A2 (pt) | 2019-03-19 |
| AU2017252192C1 (en) | 2023-06-08 |
| CN109069605A (zh) | 2018-12-21 |
| JP7320947B2 (ja) | 2023-08-04 |
| CA3019266A1 (en) | 2017-10-26 |
| WO2017182528A1 (en) | 2017-10-26 |
| AU2022203627A1 (en) | 2022-06-16 |
| US20230265156A1 (en) | 2023-08-24 |
| KR20180134935A (ko) | 2018-12-19 |
| CN109069605B (zh) | 2022-11-29 |
| US20190106477A1 (en) | 2019-04-11 |
| RU2018136760A3 (ru) | 2020-05-27 |
| IL262286A (en) | 2018-11-29 |
| AU2017252192A1 (en) | 2018-10-18 |
| IL262286B1 (en) | 2023-08-01 |
| JP2022022423A (ja) | 2022-02-03 |
| JP2019514895A (ja) | 2019-06-06 |
| KR20240015731A (ko) | 2024-02-05 |
| KR20220132023A (ko) | 2022-09-29 |
| US11485768B2 (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018136760A (ru) | НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ | |
| RU2017111657A (ru) | Новые иммуногенные пептиды | |
| JP2018504419A5 (ru) | ||
| JP2019514895A5 (ru) | ||
| CO2018008763A2 (es) | Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer | |
| CR20180423A (es) | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-0174) | |
| CO2018003659A2 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| MX2017008329A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| MX2018009958A (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cancer. | |
| CR20180295A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
| CO2021004028A2 (es) | Proceso para la preparación de composiciones de vacunas | |
| CL2019003422A1 (es) | Nuevos péptidos (seq id n°171), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| AR104675A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| RU2014135406A (ru) | Модифицированные эпитопы для усиления ответов cd4+ т-клеток | |
| CR20180591A (es) | Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer | |
| CL2018001533A1 (es) | Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer | |
| CL2019003328A1 (es) | Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244) | |
| FI3380115T3 (fi) | Peptidejä piwil1:stä | |
| MX2020011793A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| CR20180530A (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer | |
| EA202190186A1 (ru) | Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака | |
| EA202190465A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20210727 |